| Particulars (Rupees in Crores.) | Sept-2025 | Jun-2025 | Mar-2025 | Dec-2024 | Sept-2024 |
|---|---|---|---|---|---|
Gross Sales | 6,037.9 | 6,467 | 6,290.2 | 5,123.5 | 5,113.6 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 6,037.9 | 6,467 | 6,290.2 | 5,123.5 | 5,113.6 |
Other Operating Income | 85.3 | 106.7 | 237.7 | 145.6 | 123.4 |
Other Income | 109 | 154.9 | 80.6 | 57.5 | 68.5 |
Total Income | 6,232.2 | 6,728.6 | 6,608.5 | 5,326.6 | 5,305.5 |
Total Expenditure | 4,141.6 | 4,485.2 | 4,622 | 3,881.8 | 3,775.6 |
PBIDT | 2,090.6 | 2,243.4 | 1,986.5 | 1,444.8 | 1,529.9 |
Interest | 101.3 | 84.7 | 76.6 | 32 | 25.1 |
PBDT | 1,989.3 | 2,158.7 | 1,909.9 | 1,412.8 | 1,504.8 |
Depreciation | 301.9 | 238.1 | 237.9 | 229 | 233.6 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 378.8 | 230.7 | 990.6 | 39.3 | 365.6 |
Deferred Tax | 75.2 | 203.3 | -567.4 | 140.2 | 7.5 |
Reported Profit After Tax | 1,233.4 | 1,486.6 | 1,248.8 | 1,004.3 | 898.1 |
Minority Interest After NP | -20 | 54.2 | 72.8 | 2.7 | 9 |
Net Profit after Minority Interest | 1,258.6 | 1,466.8 | 1,170.9 | 1,023.5 | 911.2 |
Extra-ordinary Items | -25 | 0 | -89.49 | -0.3 | 0.3 |
Adjusted Profit After Extra-ordinary item | 1,283.6 | 1,466.8 | 1,260.39 | 1,023.8 | 910.9 |
EPS (Unit Curr.) | 12.51 | 14.58 | 11.64 | 10.17 | 9.06 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 100.6 | 100.6 | 100.6 | 100.6 | 100.6 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 34.62 | 34.68 | 31.58 | 28.19 | 29.91 |
PBDTM(%) | 32.94 | 33.38 | 30.36 | 27.57 | 29.42 |
PATM(%) | 20.42 | 22.98 | 19.85 | 19.6 | 17.56 |
Ravishanker Kovi, the founder and executive chairman of RK Pharma, commented that Zydus Life has a powerful commercial footprint.
The approved product is a biosimilar of the US reference listed drug Calan SR extended-release tablets in the same vials.
The product is a generic version of Lynparza Tablets developed by AstraZeneca.
Here are some of the stocks that may see significant price movement: Bharti Airtel, Cipla, Gland Pharma, etc.
Here are some of the stocks that may see significant price movement today: Tata Motors, TVS Motors, Zydus Lifesciences, etc.
The company also announced that it has also received approval for generic furosemide tablets for veterinary use.
Here are some of the stocks that may see significant price movement today: Adani Enterprises, JSW Infrastructure, Zydus, etc.
Earlier this week, Zydus launched ‘VaxiFlu’, a trivalent influenza vaccine aligned with WHO guidelines, becoming the first Indian company to introduce such a vaccine.
The study, known as EPICS-III, tested the drug in adults with primary biliary cholangitis (PBC) a rare, progressive liver disease that often leaves patients with limited treatment options.
The company said it will work with the US regulator to resolve the points raised as quickly as possible.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
